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Abstract
Background: High costs are a limitation to scaling up the Xpert MTB/RIF assay (Xpert) for the diagnosis of tuberculosis in
resource-constrained settings. A triaging strategy in which a sensitive but not necessarily highly specific rapid test is used to
select patients for Xpert may result in a more affordable diagnostic algorithm. To inform the selection and development of
particular diagnostics as a triage test we explored combinations of sensitivity, specificity and cost at which a hypothetical
triage test will improve affordability of the Xpert assay.
Methods: In a decision analytical model parameterized for Uganda, India and South Africa, we compared a diagnostic
algorithm in which a cohort of patients with presumptive TB received Xpert to a triage algorithm whereby only those with a
positive triage test were tested by Xpert.
Findings: A triage test with sensitivity equal to Xpert, 75% specificity, and costs of US$5 per patient tested reduced total
diagnostic costs by 42% in the Uganda setting, and by 34% and 39% respectively in the India and South Africa settings.
When exploring triage algorithms with lower sensitivity, the use of an example triage test with 95% sensitivity relative to
Xpert, 75% specificity and test costs $5 resulted in similar cost reduction, and was cost-effective by the WHO willingness-to-
pay threshold compared to Xpert for all in Uganda, but not in India and South Africa. The gain in affordability of the
examined triage algorithms increased with decreasing prevalence of tuberculosis among the cohort.
Conclusions: A triage test strategy could potentially improve the affordability of Xpert for TB diagnosis, particularly in low-
income countries and with enhanced case-finding. Tests and markers with lower accuracy than desired of a diagnostic test
may fall within the ranges of sensitivity, specificity and cost required for triage tests and be developed as such.
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Introduction
New diagnostics could substantially reduce global TB incidence
[1,2]. Nucleic acid amplification tests (NAAT) have higher
sensitivity than smear microscopy [3,4], and have high specificity.
The Xpert MTB/RIF assay [5] (Cepheid, Sunnyvale, CA, USA),
hereafter referred to as Xpert, is the first NAAT endorsed by
World Health Organization (WHO) for widespread use [6,7].
Xpert can confirm the presence of M tuberculosis and identify
rifampicin resistance-conferring mutations within 2 hours, and
increases case detection by one third compared to smear-
microscopy [4,8]. In economic evaluations the use of Xpert as
an addition to, or a replacement of sputum smear microscopy in
routine clinical settings in high-TB burden countries was
cost-effective by the WHO Choosing Interventions that are
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Cost-Effective (WHO-CHOICE) initiative’s willingness to pay
(WTP) threshold [9,10]. This threshold considers interventions to
be cost-effective if the incremental cost to avert an additional
disability-adjusted life year (DALY) is less than the country per-
capita gross domestic product (GDP) [11,12].
However, the Xpert technology requires basic laboratory
infrastructure, has relatively high cost compared to microscopy,
and does not meet all specifications of a truly point-of-care (POC)
TB diagnostic test [8,13]. WHO therefore recommends Xpert as
the initial diagnostic test in individuals with presumed MDR-TB
or HIV-associated TB, and conditionally in settings where MDR
and/or HIV is of lesser concern given the resource implications
[7,14]. The affordability of scaling up Xpert is a concern in many
high TB burden countries in Africa and Asia, where the costs to
test all persons with presumed TB in routine clinical practice with
Xpert requires 20–80% of current TB spending [15]. Further, as
Xpert is applied to populations with low TB prevalence, cost-
effectiveness rapidly decreases due to high per-diagnosis cost [9].
This may preclude scale-up for use in improved case finding
through screening, i.e. a systematic effort to identify unrecognized
disease through targeting groups in which TB prevalence is lower
[16,17] than among patients with prolonged TB symptoms
reporting to health facilities in high TB incidence countries [18].
A cheaper POC TB diagnostic test with optimized sensitivity
and specificity therefore remains a major objective of research and
development [13,19]. Some of the available technology or
biomarkers [19] that do not meet the specifications of an
optimized diagnostic POC may however be modifiable into a
triage test, to be used in a diagnostic algorithm [20], to select
patients with increased probability of having TB for confirmatory
testing by Xpert. Such a ‘triage algorithm’ could potentially reduce
diagnostic cost and thus be more affordable than offering Xpert to
all persons with presumptive TB. For a non-invasive triage test
with high sensitivity, the cost-effectiveness of a triage algorithm is
mainly a trade-off between specificity, which determines the
number of persons requiring confirmatory testing by Xpert, and
cost. In order to guide the development and selection of potential
triage tests we expanded a decision analytical model [9] with the
objective to explore combinations of sensitivity, specificity and cost
of a hypothetical triage test at which a triage algorithm is more
cost-effective than Xpert for all persons with presumptive TB.
Methods
The model was parameterized with data from a demonstration
study of Xpert in three epidemiological and economic settings:
India (low HIV prevalence, low MDR prevalence), Uganda (high
HIV prevalence, low MDR prevalence), and South Africa (high
HIV prevalence, moderately high MDR prevalence) [4] and
follows a cohort of 10 000 individuals with presumptive TB who
require diagnostic testing through the diagnostic and treatment
pathway, estimating test and treatment costs and health gains
(DALYs averted, TB cases detected) [9]. The analysis was
conducted from a TB program perspective.
We compared two diagnostic pathways (Figure 1), the Xpert-
for-all algorithm and the triage algorithm. In the Xpert-for-all
algorithm, a single sputum specimen was tested by Xpert for all
persons in the cohort. In the triage algorithm, all persons were
tested with a hypothetical triage test, and if positive were
subsequently tested by Xpert on a single sputum specimen. In
both algorithms, TB cases who remained undiagnosed due to
negative results of Xpert or the triage test, respectively, return for
re-testing after three months unless they die or self-cure within that
time. The sensitivity of the triage test is hereon referred to as the
sensitivity relative to Xpert, i.e. the proportion of cases in the
cohort detectable by Xpert that test positive by the triage test. In
the primary analysis the simplifying assumption was made that the
proportion of Xpert-detectable cases identified by the triage test
was the same in HIV-infected and HIV-uninfected TB cases. The
sensitivity and specificity of Xpert was as observed in the
demonstration study (all sites combined [4]) relative to sputum
culture as the reference standard and was stratified by HIV- and
smear-status (Table S1).
We measure and compare the effectiveness of each alternative
algorithm using disability adjusted life years (DALYs) averted, a
measure used in the estimation of the global burden of disease
[21].
For a triage algorithm to be considered by policy makers it
needs to be either as effective in identifying TB cases, but less
costly than Xpert-for-all; or if less effective, the gain in cost
reduction needs to be sufficiently high to make any loss in
effectiveness acceptable (Figure S1). In this latter case it is relevant
to report incremental cost effectiveness ratios (ICERs). These
describe how much it costs to avert an additional DALY using
Xpert-for-all compared to triage. If the ICER of the Xpert-for-all
algorithm is higher than the amount policy makers are prepared to
pay (willingness to pay (WTP) threshold) then the triage algorithm
is reported as being cost-effective. According to the WHO-
CHOICE criterion, WTP thresholds for highly cost-effective
interventions were $1,489 for India, $8,070 for South Africa, and
$487 for Uganda in 2011 [22], although lower thresholds have
been suggested [12].
We therefore began by examining the characteristics of triage
test with 100% sensitivity relative to Xpert, and determined the
combinations of triage test specificity and test cost that result in
lower total diagnostic cost of the triage algorithm compared to the
Xpert algorithm. To illustrate the results and present numerical
values of cost and effectiveness, we chose an hypothetical triage
test example with 75% specificity and per-patient test cost of $5
(example 1).
Our second analysis explored triage tests with lower sensitivity,
in which we estimated ICERs for Xpert-for-all compared to triage
algorithms with different combinations of triage test sensitivity,
specificity and cost. Our main purpose was to examine the
relationship between per-patient triage test cost and specificity for
lower levels of sensitivity. As in the primary analysis we used two-
way deterministic sensitivity analysis and varied the values of cost
and specificity, but now for pre-set levels of sensitivity. Here we
present numerical values of cost and effectiveness of hypothetical
triage test examples with sensitivity of 95% (example 2), and 85%
(example 3). As illustrations we choose 75% specificity for example
2, and 85% for example 3, in the range of what can be achieved by
e.g. chest radiography [23]. Following economic evaluation
convention the numerical values of cost and effectiveness of these
hypothetical examples are presented first, followed by the results of
the sensitivity analyses that were our main interest.
We maintained key input parameters from the published model
[9] but changed the following: we assumed 5% prevalence of
smear-positive TB, reflecting a situation of enhanced case finding
among patients attending a health facility, for instance considering
all patients with a cough of any duration [16,17]. All local costs
were reported in 2011 US$ and converted using the average
exchange rate for 2011 (imfstatext.imf.org). Diagnostic costs were
based on costing studies conducted at the demonstration sites. The
Xpert per-person test cost included costs for equipment, mainte-
nance, labour and overheads that are country specific and were
maintained from the original model [9], but were adjusted to
accommodate the US$9.98 subsidized cartridge cost [24] resulting
TB Triage Test Characteristics
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in a per-person test cost ranging from $14.01 in India to $19.23 in
Uganda (Table S1). The triage test cost was also assumed to be a
per-person test cost that combined cost to acquire, apply and
maintain the triage test. In the examples we choose $5 per-person
triage test cost as a conservative estimate. For rapid diagnostic tests
diagnosing other infectious diseases in resource-limited settings,
per-person test cost between $1 and $5 have been reported [25–
27].
We conducted several sensitivity analyses to explore the effect
on the cost-effectiveness of the Xpert-for-all compared to the
triage algorithm of changes in TB prevalence and HIV prevalence
among the cohort of patients with presumptive TB, changes in the
cost of Xpert, and of the assumption that triage test sensitivity is
relative to Xpert rather than to culture. We also investigated the
effect on cost-effectiveness if the sensitivity of a triage test would be
higher or lower in HIV-infected patients compared to HIV-
negative patients, and if HIV-infected patients would have clinical
diagnosis following (i) a negative Xpert result; (ii) a negative triage
test result, using data on sensitivity, specificity and cost of X-ray
and/or antibiotic trial taken from the demonstration study [4]
(Table S1). We also explored the effect of considerably higher cost
for MDR-TB treatment in South Africa [28]. Finally we
conducted a probabilistic sensitivity analysis using Monte Carlo
simulations to explore the effect of uncertainty around all
parameter estimates. Where it was not clear whether an ICER
was above the willingness to pay threshold, we produced
acceptability curves. These illustrate the probability that an
intervention is cost-effective given the uncertainty around any
parameter estimates.
We used TreeAge (TreeAge Software, Inc., Williamstown MA,
USA) for model construction and analyses, and transferred the
model output to MS-Excel (Microsoft Corp, Seattle WA, USA) for
further analysis. Ethical approval was not sought, as only
secondary data were used.
Results
A triage test with a relative sensitivity of 100%, a specificity of
75% and per-patient test cost of $5 reduced cohort diagnostic costs
for Uganda by 42% (Table 1, example 1). For India and South
Africa the reductions in diagnostic costs were 34% and 39%,
respectively. The reductions of total diagnostic and treatment costs
combined were 23% for Uganda, 16% for India, and 11% for
South Africa where the cost for TB and MDR treatment comprise
a greater proportion of the total cost. The proportional reduction
in diagnostic costs for other combinations of triage test specificity
Figure 1. Simplified schematic presentation of the two pathways in the model.
doi:10.1371/journal.pone.0082786.g001
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Figure 2. Combinations of cost and specificity of a triage test with 100% relative sensitivity. These combinations result in equal or
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and per-patient test cost are shown in Figures 2A-C: e.g. more
than 60% reduction could be achieved in all three settings for a
triage test with 100% relative sensitivity, 85% specificity and $2
per-patient test cost.
For triage tests with lower sensitivity (hypothetical examples 2
and 3), the percentage cases detected and effectiveness of the triage
algorithm are shown in Tables 1 and 2 respectively. For example
2, a triage test with 95% sensitivity, 75% specificity and $5 cost,
the diagnostic costs and cost reductions to be achieved were almost
the same as for example 1. The ICER of the Xpert-for-all
algorithm, compared to a triage algorithm with triage test example
2 was $491 for Uganda, i.e. one pays $491 for each additional
DALY that is averted by employing the Xpert-for-all rather than
the triage algorithm. At a WTP of $487 the probability that Xpert-
for-all is cost-effective is 49% (Figure S4) and the triage algorithm
may be the preferred choice. For India the ICERs of the Xpert-
for-all algorithm compared to triage example 2 (95% relative
sensitivity) was $662, less than half of the GDP, and for South
Africa the ICER was $669, less than 10% of the GDP, for both
countries suggesting that compared to this triage algorithm Xpert-
for-all is cost-effective by the WHO-CHOICE WTP threshold.
If the cost-effectiveness ceiling were lower than the WHO-
CHOICE WTP, certain combinations of specificity and cost
would make a triage test with lower sensitivity attractive. This is
illustrated in Figures 3A-C for Uganda: Assuming a triage per-
person test cost of $5, the ICER of Xpert-for-all compared to a
triage algorithm with 85% sensitivity and 85% specificity of the
triage test (example 3) was $174 per DALY averted (Figure 3B). If
the sensitivity were 95% (Figure 3A), the same ICER ($174 per
DALY) is expected if specificity were 40%, while many
combinations of cost and specificity would result in higher ICERs.
If a triage test had 75% sensitivity the ICERs were all below $174,
regardless of cost and specificity (Figure 3C). Similar trends for
India and South Africa are illustrated in the supplement (Figures
S2-S3).
In sensitivity analyses the ICERs of Xpert-for-all compared to a
triage algorithm rapidly increased at lower TB prevalence,
especially for prevalence of smear-positive TB ,3%, and
decreased if the prevalence of smear-positive TB increased (Figure
4A-C). Assuming 2% prevalence of smear-positive TB and a triage
test with 95% sensitivity and 75% specificity (example 2), the
ICER was $1,292 for Uganda. Assuming 15% prevalence of
smear-positive TB and a triage test with 85% sensitivity and 85%
specificity (example 3) the ICER was $57 only.
Additional sensitivity analyses are shown in Table 3. If the per-
patient test cost of Xpert reduced by $5, the ICERs of the Xpert-
for-all algorithm compared to a triage algorithm were lower, $319
per DALY averted for example 2 and $120 DALY averted for
example 3 for Uganda (Table 3). Assuming lower triage test
sensitivity in HIV-positive compared to HIV-negative patients
reduced the ICERs of Xpert-for-all in the two countries with high
HIV prevalence (Table 3). Assuming the reverse, higher sensitivity
in HIV-positive patients, made a triage algorithm more favour-
able, explained by greater mortality from undetected TB in HIV-
positive patients. The addition of clinical diagnosis after a negative
Xpert in HIV-positive patients (Table S2) increased the total cost
of the Xpert-for-all algorithm by 18%, and of triage algorithms by
4–6% for Uganda. Adding clinical diagnosis also after a negative
triage test increased the total cost of the triage algorithm by 24–
27%, partly due to treatment cost for an increased number of TB
cases diagnosed empirically without bacteriologic confirmation,
which has low specificity.
Discussion
In this decision analytical modeling study we explored the
concept of triaging patients for confirmatory testing by Xpert and
demonstrated that triage tests with high sensitivity but modest
specificity could improve the affordability of Xpert in current
clinical settings. We show a range of (combinations of) sensitivity,
specificity and cost within which a potential triage test would result
in a considerable reduction of total diagnostic costs compared to
Xpert for all patients with presumptive TB. As hypothetical
examples, for a triage test that would be as sensitive as Xpert,
approximately 40% reduction in diagnostic costs is expected for
specificity and per-patient test combinations ranging between
85%-$6 and 60%-$2. Triage tests with lower sensitivity could still
be attractive in settings where the WTP threshold for health
interventions is considerably lower than the WHO-CHOICE
threshold of one GDP per capita [12], and to target populations
with a lower TB prevalence for enhanced or active case finding.
To our knowledge no current TB tests have proven accuracy in
a triaging algorithm and cost characteristics that fall within those
ranges. A possible exception may be CXR in mass screening. The
TB diagnostics development pipeline is filling up, and biomarker
discovery projects are ongoing. Yet the ideal simple one-off highly
sensitive and highly specific diagnostic test is not available. In the
interim a test that could serve as a triage test may be a valuable
spin-off.
While our examples are hypothetical, the modelling approach
that we show could be useful when considering the feasibility of a
potential triage test. High sensitivity is an important consideration.
Triage tests with high sensitivity would have the advantage of a
wide range of cost and specificity options that ensure the triage
algorithm improves affordability, and may also avoid a costly
tendency to add clinical diagnosis if the triage test result is
negative. For the development of triage tests this implies that, if the
technology and the costs allow, a cut-off value should be chosen
that increases sensitivity at the expense of specificity, rather than
choosing the optimal trade-off between sensitivity and specificity.
Triage tests with lower sensitivity had a smaller affordability
benefit over the Xpert-for-all algorithm, but very cheap tests may
still be useful for resource limited settings where lower WTP
thresholds apply in practice [12], and decision makers with very
limited budgets have to choose between interventions with ICERS
well below $100/DALY averted [27,29]. In middle-income
countries like South Africa Xpert is cost-effective for routine TB
diagnosis [15]. In these settings triage tests would be useful as a
screening tool for active case finding at lower TB prevalence while
triage tests with lower sensitivity may not be attractive in passive
case detection. Ultimately decision maker’s choices about afford-
ability will be a trade-off between cost-effectiveness and other
important decision-making factors that vary by country [12].
We showed that the specificity of a triage test is a trade-off with
the per-patient test cost. In practice the cost to acquire and apply
the device will vary by setting, by scale, and by technology
depending on human resource, equipment and additional
consumable requirements. For instance, the cost to apply a lateral
flow device can be low in low-income countries. For rapid tests for
detection of other infectious diseases, costs of $0.34 and $1.6 per
reduced diagnostic cost of a triage pathway, compared to Xpert on all persons with presumptive TB. Panel 2A shows the Uganda setting, 2B the India
setting and 2C the South African setting.
doi:10.1371/journal.pone.0082786.g002
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patient tested in addition to the purchase of the test have been
reported [26,27]. For other technologies initial equipment cost
may be considerable, so the per-patient test cost would largely
depend on the expected number of patients that the equipment
will be used for. An example of the latter is computer-aided
reading of digital chest radiography (CAD) [30], an already
available technology with very low running costs, of which the
accuracy in a triage algorithm needs to be established [15].
In the future the cost for cartridge-based NAAT may reduce, or
at least the cost for Xpert cartridges. Assuming the equipment and
labour cost remain the same, even a cartridge cost of $3 would not
achieve the same cost reduction as the triage algorithm in our
primary analysis. The cost of cartridge-based real-time PCR
technology is not likely to reduce to the levels of e.g. lateral flow
assays and the current concessionary pricing for the Xpert
cartridges (at $9.98 each [24]) is probably already close to the
bottom price. Moreover, other elements contributing to the per-
patient test cost (such as labor cost, cost for transporting, storing
and discarding cartridges) are less variable. Therefore it is unlikely
that per-patient costs for Xpert will come down to an extent that it
much affects our conclusions.
Our analyses had several limitations. The model parameters
were obtained from observations in health facilities and the
analysis assumed that the triage and confirmatory test are
performed at the same facility and same visit. The results are
primarily applicable to improved case finding within health
facilities (e.g. offering TB testing to all persons attending a health
facility with any cough), or to congregational settings. We did in
this analysis not consider operational aspects of test implementa-
tion. Additional diagnostic delays and drop-off between triage and
confirmatory test were not included, and would lower the cost-
effectiveness of a triage algorithm, similarly as would tests with
lower sensitivity. When evaluating potential triage tests, those
would have to be considered. Costs for outreach and transporta-
Figure 3. Incremental Cost-Effectiveness Ratios (ICERs) of Xpert on all persons with presumptive TB compared to triage algorithms
for various sensitivity, specificity and cost combinations of a triage test. The figure shows the Uganda setting.
doi:10.1371/journal.pone.0082786.g003
Figure 4. Sensitivity analyses. The effect of varying the prevalence of TB among persons with presumptive TB on the Incremental Cost-
Effectiveness ratios (ICERs) for Xpert compared to triage pathways, with triage tests examples with sensitivity and specificity of 95%/75% and 85%/
85% respectively, for the Uganda (4A), India (4B) and South Africa (4C) setting.
doi:10.1371/journal.pone.0082786.g004
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tion of samples or equipment were not considered, nor were
possible effects on transmission; as far as effects on transmission
can be expected our model is conservative. Screening and active
case finding are increasingly encouraged as ways to improving
stagnating trends in TB case detection [31]. A triage test would
enhance the feasibility of screening, but the cost-effectiveness of
TB screening and mass case finding would require further study
and adjusted models.
For reasons of simplicity we assumed the sensitivity of the triage
test to be relative to Xpert, thus reflecting a proportion of TB cases
that can be detected by the confirmatory test. Assuming triage test
sensitivity to be relative to culture and independent of Xpert,
made the cost-effectiveness of triage algorithms look more
favourable compared to Xpert-for-all. We assumed the accuracy
to be independent of HIV status in the primary analysis and
showed the direction of the effect if this were different. In practice
the biological mechanism of a specific triage test will determine if
and how the sensitivity of a triage tests interacts with Xpert and
with HIV status. Overlap is expected when e.g. the same cases
with a low bacillary concentration in sputum are missed by both
tests. The results of these sensitivity analyses point out the
importance of evaluating the accuracy of potential triage tests in
combination with the presumed confirmatory tests, and in
different sub-populations including HIV-positive and negative,
early and advanced diseased. Assessing operational aspects of test
implementation is an additional requirement before the cost-
effectiveness of a specific triage test can be concluded. Our analysis
aims to contribute to decisions about which tests or technologies
may be worthwhile for further development and evaluation.
We did not include a base case of smear-microscopy followed by
X-ray and clinical diagnosis if smears are negative [9], which in all
three settings detected fewer TB cases than a triage algorithm
based on a triage test with 70% relative sensitivity (data not
shown). Lastly, our model does not consider the possibly higher
MDR treatment cost as found in South Africa [28] nor the cost for
HIV treatment [10] in the main analyses. Both would make
algorithms with the highest case detection, i.e. Xpert-for-all less
cost-effective, and thus make triage algorithms detecting fewer TB
cases look more favourable.
Conclusion
A triage test strategy to select persons for confirmatory testing
with Xpert could substantially improve the affordability of Xpert
for TB diagnosis. The affordability gain of a triage test with high
sensitivity and modest specificity is particularly large with
enhanced case finding. Further development of technologies that
do not meet specification of a TB diagnostic POC, but may be
suitable as a triage test, deserve encouragement.
Supporting Information
Figure S1 Cost-effectiveness plane comparing two di-
agnostic strategies: Xpert-for-all (Xpert) as the compar-
Table 3. Sensitivity analyses.
Assumption Triage test example
ICER of Xpert-for-all compared to
triage algorithm (Costs per DALY,
2011 US$)
Uganda India
South
Africa
Primary estimate 2. 95% sensitivity, 75% specificity, cost $5* 491 662 695
3. 85% sensitivity, 85% specificity, cost $5 174 213 281
Xpert cartridge price changes –/+ $5 2. 95% sensitivity, 75% specificity, cost $5 319–662 329–996 495–894
3. 85% sensitivity, 85% specificity, cost $5 120–227 123–304 218–344
HIV-prevalence –/+ 25% in high HIV settings 2. 95% sensitivity, 75% specificity, cost $5 551–442 803–614
3. 85% sensitivity, 85% specificity, cost $5 184–165 301–266
Triage test sensitivity relative to culture and independent of Xpert
sensitivity
2. 95% sensitivity, 75% specificity, cost $5 624 846 867
3. 85% sensitivity, 85% specificity, cost $5 203 244 321
Triage test sensitivity lower in HIV-positive compared to HIV-negative
patients
2. 90% in HIV+, 100% in HIV–, 75% spec, $5 326 23,380 467
3. 75% in HIV+, 95% in HIV–, 85% spec, $5 136 760 230
Triage test sensitivity higher in HIV-positive compared to HIV-negative
patients
2. 100% in HIV+, 90% in HIV–, 75% spec, $5 723 295 1104
3. 95% in HIV+, 75% in HIV–, 75% spec, $5 190 114 312
Increase upper range of MDR treatment in South Africa to $17,164 [28] 2. 95% sensitivity, 75% specificity, cost $5 753
3. 85% sensitivity, 85% specificity, cost $5 336
The effect of assumptions on the ICER of Xpert-for-all compared to triage pathway with different triage test examples.
*per-patient test cost including cost to acquire, apply and maintain the test.
ICER = incremental cost-effectiveness ratio.
DALY =disability adjusted life year.
MDR= multi-drug resistant.
Xpert = GeneXpert MTB/RIF assay.
HIV+ =HIV positive; HIV– = HIV negative; spec = specificity.
doi:10.1371/journal.pone.0082786.t003
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ator and a triage algorithm (triage test, if positive
followed by Xpert) as the base case.
(TIF)
Figure S2 Incremental Cost-Effectiveness Ratios
(ICERs) of ’Xpert on all patients compared to triage
algorithms for various sensitivity, specificity and cost
combinations of a triage test in the India setting.
(TIF)
Figure S3 Incremental Cost-Effectiveness Ratios
(ICERs) of ’Xpert on all patients compared to triage
algorithms for various sensitivity, specificity and cost
combinations of a triage test in the South Africa setting.
(TIF)
Figure S4 Acceptability cure comparing Xpert-for-all
with a triage algorithm based on a triage test with 95%
sensitivity, 75% specificity and per-patient test cost of
$5, in the Uganda setting (GDP $487).
(TIF)
Table S1 Model inputs: cohort composition, diagnostic
parameters and costs, by country setting.
(DOCX)
Table S2 Effect of adding clinical diagnosis in HIV-
infected in the Uganda setting, on total cohort cost and
costs per patient diagnosed by Xpert-for-all and Triage
examples. For a cohort of 10 000 patients with presumed
TB with 5% prevalence of smear-positive TB.
(DOCX)
Methods S1 METHODS expanded
(DOCX)
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